Skip to main content

A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive

Clinical Trial Grant
Duke Scholars

Administered By

Pediatrics, Neurology

Awarded By

Noema Pharma

Start Date

March 1, 2022

End Date

May 1, 2024
 

Administered By

Pediatrics, Neurology

Awarded By

Noema Pharma

Start Date

March 1, 2022

End Date

May 1, 2024